LAVA Therapeutics Announces Pricing of Initial Public Offering
LAVA Therapeutics B.V. (Nasdaq: LVTX) priced its initial public offering of 6,700,000 common shares at $15.00 each, aiming to raise approximately $100.5 million before expenses. The underwriters have a 30-day option to purchase an additional 1,005,000 shares at the same price. Trading is expected to commence on the Nasdaq Global Select Market on March 25, 2021. The offering is projected to close on March 29, 2021, subject to standard conditions. J.P. Morgan, Jefferies, and SVB Leerink are managing the offering.
- Initial public offering priced at $15.00 per share, intending to raise $100.5 million.
- Additional share purchase option for underwriters could increase total raised funds.
- Expected trading start on a reputable exchange (Nasdaq Global Select Market).
- Potential dilution of existing shares due to the issuance of new shares.
UTRECHT, The Netherlands and PHILADELPHIA, March 24, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics B.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the pricing of its initial public offering of 6,700,000 common shares at a public offering price of
Gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by LAVA, are expected to be
J.P. Morgan, Jefferies and SVB Leerink are acting as joint book-running managers for the offering. Kempen & Co is acting as lead manager for the offering.
The registration statement relating to these securities became effective on March 24, 2021. The offering will be made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus_eqfi@jpmchase.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388 or by email at prospectus_department@Jefferies.com; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbleerink.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding LAVA’s expectations regarding the commencement of trading of its shares on the Nasdaq Global Select Market and the completion and timing of the closing of offering. Forward-looking statements are based on LAVA’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the satisfaction of customary closing conditions and the completion of the offering. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the offering to be filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and LAVA undertakes no duty to update such information except as required under applicable law.
Company Contact:
FAQ
What is the price of LAVA Therapeutics' initial public offering?
How much capital does LAVA Therapeutics expect to raise from the IPO?
When is LAVA Therapeutics expected to start trading on Nasdaq?
What is the ticker symbol for LAVA Therapeutics?
Who are the underwriters for LAVA Therapeutics' IPO?
